Clinical Scorecard: This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
At a Glance
| Category | Detail |
|---|---|
| Condition | Duchenne muscular dystrophy |
| Key Mechanisms | AAV microdystrophin gene therapy |
| Target Population | Patients with Duchenne muscular dystrophy |
| Care Setting | Clinical trial setting |
Key Highlights
- 93% of evaluable participants achieved at least 10% microdystrophin expression at week 12.
- Editing was sustained for at least three months after the last dose.
- No serious adverse events or clinically meaningful liver test elevations reported.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Evaluable participants in the AFFINITY DUCHENNE trial
One-time AAV microdystrophin gene therapy
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
